ArticleAmerican journal of preventive medicine2026
Productivity Losses From Substance Use Disorder in the U.S. in 2023.
Article in American journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionInformation on morbidity-related productivity losses attributable to substance use disorder is limited. This study estimates morbidity-related productivity losses attributable to substance use disorder among U.S. adults aged ≥18 years in 2023.
methodsMorbidity-related productivity losses attributable to substance use disorder were estimated using the human capital approach. Using a regression-based approach, the 2021-2023 National Survey on Drug Use and Health data, along with other data and published literature, were used to estimate the cost of absenteeism, presenteeism, household productivity loss, and inability to work attributable to substance use disorder. All costs were estimated for 2023, and all analyses were conducted in 2025.
resultsTotal morbidity-related productivity loss attributable to substance use disorder among U.S. adults was estimated to be $92.65 billion (95% prediction interval=$57.90, $136.48 billion) in 2023. Inability to work cost accounted for $45.25 billion (95% prediction interval=$28.29, $65.88 billion), followed by absenteeism cost of $25.65 billion (95% prediction interval=$15.11, $39.93 billion), presenteeism cost of $12.06 billion (95% prediction interval=$9.26, $15.41 billion), and cost of household productivity loss of $9.68 billion (95% prediction interval=$5.25, $15.26 billion).
conclusionsTotal morbidity-related productivity losses attributable to substance use disorder in the U.S. are substantial, amounting to $92.65 billion in 2023. Given that these estimates depend on the prevalence of substance use disorder and the amount of lost productive time, evidence-based prevention efforts and policies addressing them can help reduce these losses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.